JP2004528334A - 新規な化合物 - Google Patents

新規な化合物 Download PDF

Info

Publication number
JP2004528334A
JP2004528334A JP2002583393A JP2002583393A JP2004528334A JP 2004528334 A JP2004528334 A JP 2004528334A JP 2002583393 A JP2002583393 A JP 2002583393A JP 2002583393 A JP2002583393 A JP 2002583393A JP 2004528334 A JP2004528334 A JP 2004528334A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
methyl
group
cyclopropylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002583393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528334A5 (enExample
Inventor
ユン−シン・チェン
ミロスラウ・トーマシェウスキ
クリストファー・ウォールポール
フア・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004528334A publication Critical patent/JP2004528334A/ja
Publication of JP2004528334A5 publication Critical patent/JP2004528334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2002583393A 2001-04-20 2002-04-18 新規な化合物 Pending JP2004528334A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101387A SE0101387D0 (sv) 2001-04-20 2001-04-20 Novel compounds
PCT/SE2002/000769 WO2002085866A1 (en) 2001-04-20 2002-04-18 Novel compounds

Publications (2)

Publication Number Publication Date
JP2004528334A true JP2004528334A (ja) 2004-09-16
JP2004528334A5 JP2004528334A5 (enExample) 2005-12-22

Family

ID=20283822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002583393A Pending JP2004528334A (ja) 2001-04-20 2002-04-18 新規な化合物

Country Status (25)

Country Link
US (2) US7030139B2 (enExample)
EP (1) EP1390350A1 (enExample)
JP (1) JP2004528334A (enExample)
KR (1) KR20040022421A (enExample)
CN (1) CN1250531C (enExample)
AR (1) AR035959A1 (enExample)
BG (1) BG108271A (enExample)
BR (1) BR0208907A (enExample)
CA (1) CA2444381A1 (enExample)
CZ (1) CZ20032833A3 (enExample)
EE (1) EE200300524A (enExample)
HU (1) HUP0303825A3 (enExample)
IL (1) IL158142A0 (enExample)
IS (1) IS6971A (enExample)
MX (1) MXPA03009558A (enExample)
MY (1) MY134568A (enExample)
NO (1) NO20034665L (enExample)
NZ (1) NZ528403A (enExample)
PL (1) PL366517A1 (enExample)
RU (1) RU2312864C2 (enExample)
SE (1) SE0101387D0 (enExample)
SK (1) SK13032003A3 (enExample)
UA (1) UA76743C2 (enExample)
WO (1) WO2002085866A1 (enExample)
ZA (1) ZA200307752B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536918A (ja) * 2006-03-06 2009-10-22 ファイザー株式会社 スルホニルベンゾイミダゾール誘導体
JP2014520886A (ja) * 2011-07-18 2014-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズアミド類

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301698D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SI1637527T1 (sl) * 2003-06-26 2013-07-31 Takeda Pharmaceutical Company Limited Modulator kanabinoidnega receptorja
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005037798A2 (en) * 2003-10-16 2005-04-28 Cara Therapeutics, Inc Amide or thiomide derivatives and their use in the treatment of pain
EP1797075A1 (en) * 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
JP2008514589A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用iiii
WO2006033628A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
UA87327C2 (ru) * 2004-09-24 2009-07-10 Астразенека Аб Производные бензимидазола, композиция, которая их содержит, их получение и применение
CA2582512A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
EP1797077B1 (en) * 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514594A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用i
WO2006033630A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
BRPI0517369A (pt) 2004-10-27 2008-10-07 Hoffmann La Roche compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
EP1809607B1 (en) * 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
WO2006097808A1 (en) * 2005-03-15 2006-09-21 Pfizer Japan Inc. Benzimidazolone derivatives as cb2 receptor ligands
WO2006116399A2 (en) 2005-04-28 2006-11-02 Ferring B.V. Use of novel compounds for ibd treatment
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007091950A1 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
PL2081572T3 (pl) 2006-07-04 2010-07-30 Janssen Pharmaceutica Nv Benzimidazolowe związki antagonistyczne wobec receptora kannabinoidowego zawierające podstawioną grupę heterocykliczną
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2907784B1 (fr) * 2006-10-27 2009-02-13 Sod Conseils Rech Applic Derives phenyliques et leur utilisation comme medicament
WO2009116074A2 (en) * 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
DK2536285T3 (en) 2010-02-18 2018-07-16 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use
CN102977056B (zh) * 2012-11-28 2014-11-26 深圳万乐药业有限公司 N-苄氧羰基-3-氟-4-吗啉基苯胺的合成方法
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN107531679B (zh) * 2016-03-18 2021-07-02 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945044A (en) * 1957-07-12 1960-07-12 Ciba Pharm Prod Inc Certain 1-(diethyl-aminoethyl), 5-amino, 2-benzyl or substituted benzyl, benzimidazoles
FR1481049A (fr) 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
US5620978A (en) * 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
PL182517B1 (pl) * 1994-06-10 2002-01-31 Byk Gulden Lomberg Chem Fab Tiopirydyny do zwalczania bakterii Helicobacter
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536918A (ja) * 2006-03-06 2009-10-22 ファイザー株式会社 スルホニルベンゾイミダゾール誘導体
JP2014520886A (ja) * 2011-07-18 2014-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンズアミド類

Also Published As

Publication number Publication date
US20060135554A1 (en) 2006-06-22
WO2002085866A1 (en) 2002-10-31
SK13032003A3 (sk) 2005-01-03
AR035959A1 (es) 2004-07-28
CA2444381A1 (en) 2002-10-31
HUP0303825A2 (hu) 2004-03-01
UA76743C2 (uk) 2006-09-15
SE0101387D0 (sv) 2001-04-20
IS6971A (is) 2003-09-29
MXPA03009558A (es) 2004-02-12
US20040116465A1 (en) 2004-06-17
RU2312864C2 (ru) 2007-12-20
EE200300524A (et) 2004-02-16
HUP0303825A3 (en) 2005-06-28
NO20034665D0 (no) 2003-10-17
CZ20032833A3 (en) 2004-05-12
EP1390350A1 (en) 2004-02-25
CN1250531C (zh) 2006-04-12
IL158142A0 (en) 2004-03-28
BR0208907A (pt) 2004-04-20
CN1503787A (zh) 2004-06-09
KR20040022421A (ko) 2004-03-12
PL366517A1 (en) 2005-02-07
US7030139B2 (en) 2006-04-18
BG108271A (bg) 2004-12-30
NZ528403A (en) 2005-05-27
MY134568A (en) 2007-12-31
NO20034665L (no) 2003-12-10
RU2003129638A (ru) 2005-04-10
ZA200307752B (en) 2005-01-03

Similar Documents

Publication Publication Date Title
JP2004528334A (ja) 新規な化合物
JP7094989B2 (ja) シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト
AU2008206759B2 (en) Nicotinic acetylcholine receptor modulators
EP1771441B1 (de) Neue carbonsäureamide als faktor xa-inhibitoren
NL1030324C2 (nl) Sulfonylbenzimidazoolderivaten.
CA2565065A1 (en) Therapeutic compounds: pyridine as scaffold
JP4896721B2 (ja) ベンゾイミダゾール誘導体、それを含む組成物、その製造方法およびその使用
JP2008519833A (ja) インダゾールスルホンアミド誘導体
CN100455580C (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
JP2007516284A (ja) オピオイド受容体拮抗物質
DE60224723T2 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
US20070072853A1 (en) Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof
WO2001014342A1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2007506724A (ja) ベンゾイミダゾール誘導体、それを含む組成物、その製造およびその使用
US20070082899A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE69329645T2 (de) Imidazol-, triazol- und tetrazolderivate
US20080306044A1 (en) Spirobenzoazepanes as vasopressin antagonists
WO2006097808A1 (en) Benzimidazolone derivatives as cb2 receptor ligands
AU2002307586A1 (en) Novel compounds
JP2007522209A (ja) ピロロキノリン誘導体及びピペリドキノリン誘導体、それらの製造、それらを含有する組成物及びそれらの使用
EP1220844B1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
NZ538692A (en) Chemical process involving selective reduction of a nitro moiety
CA2382892A1 (en) Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions
TW201627290A (zh) 具有抗疼痛之多重模式活性的哌衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090421